Insider transactions

EDGAR

ORIC Pharmaceuticals, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
16 transactions, 238,614 shares
Sum of shares × price per share: 2,959,893.358

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 59

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-10-20 Filed 2026-10-21Piscitelli Dominic Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)14,0004.36
61,040

Derived: shares × price per share. Exact value 61040.00.

83,828Direct (D) Yes— Open filing 0001695028-26-000012 Read from the filing’s XML Dispute this row
2026-10-20 Filed 2026-10-21Piscitelli Dominic Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)14,00013.5279
189,390.6

Derived: shares × price per share. Exact value 189390.6000.

69,828Direct (D) Yes
F1, F2
  • F1 The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026.
  • F2 Represents the weighted average share price of an aggregate total of 14,000 shares sold in the price range of $13.50 to $13.65 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Open filing 0001695028-26-000012 Read from the filing’s XML Dispute this row
2026-10-20 Filed 2026-10-21Piscitelli Dominic Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (right to buy) — underlying Common Stock (14,000) — exercise price 4.36
Disposed (D)14,0000—64,500Direct (D) Yes— Open filing 0001695028-26-000012 Read from the filing’s XML Dispute this row
2026-10-01 Filed 2026-10-02Heyman Richard A. Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)3,5001.60
5,600

Derived: shares × price per share. Exact value 5600.00.

41,800Direct (D) Yes— Open filing 0001584759-26-000017 Read from the filing’s XML Dispute this row
2026-10-01 Filed 2026-10-02Heyman Richard A. Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)3,50012.9141
45,199.35

Derived: shares × price per share. Exact value 45199.3500.

38,300Direct (D) Yes
F1, F2
  • F1 The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC.
  • F2 This transaction was executed in multiple trades at prices ranging from $12.57 to $13.39. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Open filing 0001584759-26-000017 Read from the filing’s XML Dispute this row
2026-10-01 Filed 2026-10-02Heyman Richard A. Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)3,20012.9141
41,325.12

Derived: shares × price per share. Exact value 41325.1200.

203,472Indirect (I) See footnoteYes
F1, F2, F3
  • F1 The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC.
  • F2 This transaction was executed in multiple trades at prices ranging from $12.57 to $13.39. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  • F3 The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares.
Open filing 0001584759-26-000017 Read from the filing’s XML Dispute this row
2026-10-01 Filed 2026-10-02Heyman Richard A. Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (right to buy) — underlying Common Stock (3,500) — exercise price 1.60
Disposed (D)3,5000—26,700Direct (D) Yes
F4
  • F4 The shares subject to the option are fully vested and immediately exercisable.
Open filing 0001584759-26-000017 Read from the filing’s XML Dispute this row
2026-09-28 Filed 2026-09-29Piscitelli Dominic Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)13,4004.36
58,424

Derived: shares × price per share. Exact value 58424.00.

83,228Direct (D) Yes— Open filing 0001695028-26-000010 Read from the filing’s XML Dispute this row
2026-09-28 Filed 2026-09-29Piscitelli Dominic Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)13,40013.5267
181,257.78

Derived: shares × price per share. Exact value 181257.7800.

69,828Direct (D) Yes
F1, F2
  • F1 The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026.
  • F2 Represents the weighted average share price of an aggregate total of 13,400 shares sold in the price range of $13.50 to $13.575 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Open filing 0001695028-26-000010 Read from the filing’s XML Dispute this row
2026-09-28 Filed 2026-09-29Piscitelli Dominic Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (right to buy) — underlying Common Stock (13,400) — exercise price 4.36
Disposed (D)13,4000—78,500Direct (D) Yes— Open filing 0001695028-26-000010 Read from the filing’s XML Dispute this row
2026-09-24 Filed 2026-09-25Piscitelli Dominic Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)6004.36
2,616

Derived: shares × price per share. Exact value 2616.00.

70,428Direct (D) Yes— Open filing 0001695028-26-000008 Read from the filing’s XML Dispute this row
2026-09-24 Filed 2026-09-25Piscitelli Dominic Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)10013.50
1,350

Derived: shares × price per share. Exact value 1350.00.

70,328Direct (D) Yes
F1
  • F1 The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026.
Open filing 0001695028-26-000008 Read from the filing’s XML Dispute this row
2026-09-24 Filed 2026-09-25Piscitelli Dominic Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)50013.505
6,752.5

Derived: shares × price per share. Exact value 6752.500.

69,828Direct (D) Yes
F1
  • F1 The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026.
Open filing 0001695028-26-000008 Read from the filing’s XML Dispute this row
2026-09-24 Filed 2026-09-25Piscitelli Dominic Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (right to buy) — underlying Common Stock (600) — exercise price 4.36
Disposed (D)6000—91,900Direct (D) Yes— Open filing 0001695028-26-000008 Read from the filing’s XML Dispute this row
2026-08-26 Filed 2026-08-28Piscitelli Dominic Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)52,0004.36
226,720

Derived: shares × price per share. Exact value 226720.00.

121,828Direct (D) Yes
F1
  • F1 Includes 1,680 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan.
Open filing 0001695028-26-000006 Read from the filing’s XML Dispute this row
2026-08-26 Filed 2026-08-28Piscitelli Dominic Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)25,0006
150,000

Derived: shares × price per share. Exact value 150000.

146,828Direct (D) Yes— Open filing 0001695028-26-000006 Read from the filing’s XML Dispute this row
2026-08-26 Filed 2026-08-28Piscitelli Dominic Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)77,00013.6859
1,053,814.3

Derived: shares × price per share. Exact value 1053814.3000.

69,828Direct (D) Yes
F2
  • F2 The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026.
Open filing 0001695028-26-000006 Read from the filing’s XML Dispute this row
2026-08-26 Filed 2026-08-28Piscitelli Dominic Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (right to buy) — underlying Common Stock (52,000) — exercise price 4.36
Disposed (D)52,0000—92,500Direct (D) Yes— Open filing 0001695028-26-000006 Read from the filing’s XML Dispute this row
2026-08-26 Filed 2026-08-28Piscitelli Dominic Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (right to buy) — underlying Common Stock (25,000) — exercise price 6
Disposed (D)25,0000—120,000Direct (D) Yes
F3
  • F3 25% of the shares subject to the option vested on February 1, 2024, and 1/36th of the remaining shares subject to the option shall vest each month thereafter.
Open filing 0001695028-26-000006 Read from the filing’s XML Dispute this row
2026-07-24 Filed 2026-07-28Heyman Richard A. Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)3,5001.60
5,600

Derived: shares × price per share. Exact value 5600.00.

45,300Direct (D) Yes— Open filing 0001584759-26-000015 Read from the filing’s XML Dispute this row
2026-07-24 Filed 2026-07-28Heyman Richard A. Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)7,00012.02
84,140

Derived: shares × price per share. Exact value 84140.00.

38,300Direct (D) Yes
F1
  • F1 The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC.
Open filing 0001584759-26-000015 Read from the filing’s XML Dispute this row
2026-07-24 Filed 2026-07-28Heyman Richard A. Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)6,10012.02
73,322

Derived: shares × price per share. Exact value 73322.00.

206,672Indirect (I) See footnoteYes
F1, F2
  • F1 The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC.
  • F2 The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares.
Open filing 0001584759-26-000015 Read from the filing’s XML Dispute this row
2026-07-24 Filed 2026-07-28Heyman Richard A. Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (right to buy) — underlying Common Stock (3,500) — exercise price 1.60
Disposed (D)3,5000—30,200Direct (D) Yes
F3
  • F3 The shares subject to the option are fully vested and immediately exercisable.
Open filing 0001584759-26-000015 Read from the filing’s XML Dispute this row
2026-07-06 Filed 2026-07-08Heyman Richard A. Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)30012
3,600

Derived: shares × price per share. Exact value 3600.

212,772Indirect (I) See footnoteYes
F1, F2
  • F1 The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC.
  • F2 The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares.
Open filing 0001584759-26-000012 Read from the filing’s XML Dispute this row
2026-02-24 Filed 2026-02-26Piscitelli Dominic Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)52,0004.36
226,720

Derived: shares × price per share. Exact value 226720.00.

120,148Direct (D) Yes— Open filing 0001695028-26-000004 Read from the filing’s XML Dispute this row
2026-02-24 Filed 2026-02-26Piscitelli Dominic Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)52,00013.5132
702,686.4

Derived: shares × price per share. Exact value 702686.4000.

68,148Direct (D) Yes
F1, F2
  • F1 The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2025.
  • F2 Represents the weighted average share price of an aggregate total of 52,000 shares sold in the price range of $13.50 to $13.53 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Open filing 0001695028-26-000004 Read from the filing’s XML Dispute this row
2026-02-24 Filed 2026-02-26Piscitelli Dominic Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (right to buy) — underlying Common Stock (52,000) — exercise price 4.36
Disposed (D)52,0000—144,500Direct (D) Yes— Open filing 0001695028-26-000004 Read from the filing’s XML Dispute this row
2026-01-16 Filed 2026-01-20Heyman Richard A. Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)3,50012.0046
42,016.1

Derived: shares × price per share. Exact value 42016.1000.

41,800Direct (D) Yes
F1, F2
  • F1 The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC.
  • F2 Represents the weighted average share price of an aggregate total of 6,700 shares sold in the price range of $12.00 to $12.03 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Open filing 0001584759-26-000006 Read from the filing’s XML Dispute this row
2026-01-16 Filed 2026-01-20Heyman Richard A. Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)3,20012.0046
38,414.72

Derived: shares × price per share. Exact value 38414.7200.

213,072Indirect (I) See footnoteYes
F1, F2, F3
  • F1 The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC.
  • F2 Represents the weighted average share price of an aggregate total of 6,700 shares sold in the price range of $12.00 to $12.03 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • F3 The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares.
Open filing 0001584759-26-000006 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-06Chacko Jacob Director · Officer: PRESIDENT AND CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (675,000) — exercise price 8.17
Acquired (A)675,0000—675,000Direct (D) No
F1
  • F1 25% of the shares subject to the option shall vest on January 2, 2027, and 1/36th of the remaining shares subject to the option shall vest each month thereafter.
Open filing 0001608936-26-000002 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-06Chacko Jacob Director · Officer: PRESIDENT AND CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Unit — underlying Common Stock (112,500)
Acquired (A)112,5000—112,500Direct (D) No
F2, F3
  • F2 Each restricted stock unit (RSU) represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock.
  • F3 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2026, December 15, 2027 and December 15, 2028.
Open filing 0001608936-26-000002 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-06Hoerter Steven L. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (40,000) — exercise price 8.17
Acquired (A)40,0000—40,000Direct (D) No
F1
  • F1 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026.
Open filing 0001533451-26-000002 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-06Kunkel Lori Anne Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (40,000) — exercise price 8.17
Acquired (A)40,0000—40,000Direct (D) No
F1
  • F1 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026.
Open filing 0001536368-26-000002 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-06Dier Mardi Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (40,000) — exercise price 8.17
Acquired (A)40,0000—40,000Direct (D) No
F1
  • F1 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026.
Open filing 0001574591-26-000002 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-06Piscitelli Dominic Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (206,500) — exercise price 8.17
Acquired (A)206,5000—206,500Direct (D) No
F1
  • F1 25% of the shares subject to the option shall vest on January 2, 2027, and 1/36th of the remaining shares subject to the option shall vest each month thereafter.
Open filing 0001695028-26-000002 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-06Piscitelli Dominic Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Unit — underlying Common Stock (34,500)
Acquired (A)34,5000—34,500Direct (D) No
F2, F3
  • F2 Each restricted stock unit (RSU) represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock.
  • F3 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2026, December 15, 2027 and December 15, 2028.
Open filing 0001695028-26-000002 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-06Heyman Richard A. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (40,000) — exercise price 8.17
Acquired (A)40,0000—40,000Direct (D) No
F1
  • F1 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026.
Open filing 0001584759-26-000003 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-06You Angie Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (40,000) — exercise price 8.17
Acquired (A)40,0000—40,000Direct (D) No
F1
  • F1 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026.
Open filing 0001647664-26-000002 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-06Multani Pratik S Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (214,000) — exercise price 8.17
Acquired (A)214,0000—214,000Direct (D) No
F1
  • F1 25% of the shares subject to the option shall vest on January 2, 2027, and 1/36th of the remaining shares subject to the option shall vest each month thereafter.
Open filing 0001586894-26-000002 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-06Multani Pratik S Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Unit — underlying Common Stock (35,500)
Acquired (A)35,5000—35,500Direct (D) No
F2, F3
  • F2 Each restricted stock unit (RSU) represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock.
  • F3 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2026, December 15, 2027 and December 15, 2028.
Open filing 0001586894-26-000002 Read from the filing’s XML Dispute this row
2025-12-16 Filed 2025-12-17Multani Pratik S Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)10,7209.0605
97,128.56

Derived: shares × price per share. Exact value 97128.5600.

68,149Direct (D) No
F3, F4
  • F3 Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person.
  • F4 Represents the weighted average share price of an aggregate total of 10,720 shares sold in the price range of $9.0449 to $9.1451 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Open filing 0001586894-25-000005 Read from the filing’s XML Dispute this row
2025-12-16 Filed 2025-12-17Piscitelli Dominic Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)10,7209.0604
97,127.488

Derived: shares × price per share. Exact value 97127.4880.

68,148Direct (D) No
F3, F4
  • F3 Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person.
  • F4 Represents the weighted average share price of an aggregate total of 10,720 shares sold in the price range of $9.0396 to $9.1953 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Open filing 0001695028-25-000008 Read from the filing’s XML Dispute this row
2025-12-16 Filed 2025-12-17Chacko Jacob Director · Officer: PRESIDENT AND CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)33,3749.06
302,368.44

Derived: shares × price per share. Exact value 302368.44.

581,711Direct (D) No
F2, F3
  • F2 Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person.
  • F3 Represents the weighted average share price of an aggregate total of 33,374 shares sold in the price range of $9.0257 to $9.095 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Open filing 0001608936-25-000014 Read from the filing’s XML Dispute this row
2025-12-15 Filed 2025-12-17Multani Pratik S Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)29,3330—78,869Direct (D) No
F1, F2
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the Issuer) Common Stock.
  • F2 Includes an aggregate of 2,771 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan.
Open filing 0001586894-25-000005 Read from the filing’s XML Dispute this row
2025-12-15 Filed 2025-12-17Multani Pratik S Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Unit — underlying Common Stock (8,000)
Disposed (D)8,0000—0Direct (D) No
F1, F5
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the Issuer) Common Stock.
  • F5 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025.
Open filing 0001586894-25-000005 Read from the filing’s XML Dispute this row
2025-12-15 Filed 2025-12-17Multani Pratik S Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Unit — underlying Common Stock (10,000)
Disposed (D)10,0000—10,000Direct (D) No
F1, F6
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the Issuer) Common Stock.
  • F6 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026.
Open filing 0001586894-25-000005 Read from the filing’s XML Dispute this row
2025-12-15 Filed 2025-12-17Multani Pratik S Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Unit — underlying Common Stock (11,333)
Disposed (D)11,3330—22,667Direct (D) No
F1, F7
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the Issuer) Common Stock.
  • F7 1/3 of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027.
Open filing 0001586894-25-000005 Read from the filing’s XML Dispute this row
2025-12-15 Filed 2025-12-17Piscitelli Dominic Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)29,3330—78,868Direct (D) No
F1, F2
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the Issuer) Common Stock.
  • F2 Includes 1,218 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan.
Open filing 0001695028-25-000008 Read from the filing’s XML Dispute this row
2025-12-15 Filed 2025-12-17Piscitelli Dominic Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Unit — underlying Common Stock (8,000)
Disposed (D)8,0000—0Direct (D) No
F1, F5
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the Issuer) Common Stock.
  • F5 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025.
Open filing 0001695028-25-000008 Read from the filing’s XML Dispute this row
2025-12-15 Filed 2025-12-17Piscitelli Dominic Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Unit — underlying Common Stock (10,000)
Disposed (D)10,0000—10,000Direct (D) No
F1, F6
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the Issuer) Common Stock.
  • F6 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026.
Open filing 0001695028-25-000008 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.

Showing 1–50 of 215

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
Nextech Invest Ltd. 7,162,637 SH96,480,720 dollarsUnchanged Prior quarter: 7,162,637Open filing 0001595430-26-000015 Filed 2026-11-16 Dispute this row
BlackRock, Inc. Partly reported under another manager6,979,451 SH94,013,206 dollarsHigher by 155,478 Prior quarter: 6,823,973Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
PRICE T ROWE ASSOCIATES INC /MD/ Partly reported under another manager5,088,495 SH68,543 dollarsLower by 1,529,059 Prior quarter: 6,617,554Open filing 0000080255-26-000736 Filed 2026-11-16 Dispute this row
AIHC Capital Management Ltd 4,630,986 SH62,379,381 dollarsHigher by 802,526 Prior quarter: 3,828,460Open filing 0001172661-26-005109 Filed 2026-11-16 Dispute this row
SR ONE CAPITAL MANAGEMENT, LP 4,615,384 SH62,169,223 dollarsUnchanged Prior quarter: 4,615,384Open filing 0001012975-26-001062 Filed 2026-11-16 Dispute this row
STATE STREET CORP Partly reported under another manager4,126,317 SH55,581,490 dollarsLower by 767,683 Prior quarter: 4,894,000Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
NEA Management Company, LLC 4,118,621 SH55,477,825 dollarsUnchanged Prior quarter: 4,118,621Open filing 0001072613-26-000901 Filed 2026-11-16 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 4,072,661 SH54,858,744 dollarsHigher by 121,492 Prior quarter: 3,951,169Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
VIKING GLOBAL INVESTORS LP 3,562,915 SH47,992,465 dollarsLower by 1,563,847 Prior quarter: 5,126,762Open filing 0001103804-26-000010 Filed 2026-11-16 Dispute this row
Column Group LLC 3,540,777 SH47,694,266 dollarsUnchanged Prior quarter: 3,540,777Open filing 0001193125-26-463528 Filed 2026-11-16 Dispute this row
Siren, L.L.C. Partly reported under another manager3,358,192 SH45,234,846 dollarsHigher by 360,000 Prior quarter: 2,998,192Open filing 0002005245-26-000013 Filed 2026-11-12 Dispute this row
ALKEON CAPITAL MANAGEMENT LLC Partly reported under another manager3,239,096 SH43,630,623 dollarsLower by 500,000 Prior quarter: 3,739,096Open filing 0000919574-26-007849 Filed 2026-11-16 Dispute this row
EcoR1 Capital, LLC 3,028,116 SH40,788,723 dollarsLower by 3,700,000 Prior quarter: 6,728,116Open filing 0000935836-26-000577 Filed 2026-11-16 Dispute this row
Venrock Adviser, LLC 2,944,056 SH39,656,434 dollarsLower by 1,375,709 Prior quarter: 4,319,765Open filing 0001615982-26-000019 Filed 2026-11-16 Dispute this row
FMR LLC Partly reported under another manager2,631,943 SH35,452,272 dollarsLower by 3,532 Prior quarter: 2,635,475Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
D. E. Shaw Co., Inc. Partly reported under another manager2,453,873 SH33,053,670 dollarsHigher by 873,657 Prior quarter: 1,580,216Open filing 0001104659-26-128287 Filed 2026-11-16 Dispute this row
Defilade Capital Management, L.P. 2,272,497 SH30,610,535 dollarsHigher by 1,224,807 Prior quarter: 1,047,690Open filing 0002088557-26-000010 Filed 2026-11-16 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager2,193,715 SH29,555,467 dollarsHigher by 103,626 Prior quarter: 2,090,089Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
CITADEL ADVISORS LLC Partly reported under another manager2,111,325 SH28,439,548 dollarsLower by 483,974 Prior quarter: 2,595,299Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
MORGAN STANLEY Partly reported under another manager2,036,262 SH27,428,449 dollarsHigher by 242,242 Prior quarter: 1,794,020Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
DIMENSIONAL FUND ADVISORS LP Partly reported under another manager1,900,144 SH25,594,064 dollarsHigher by 98,745 Prior quarter: 1,801,399Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row
FRANKLIN TEMPLETON INC Partly reported under another manager1,886,170 SH17,616,828 dollarsHigher by 88,793 Prior quarter: 1,797,377Open filing 0000038777-26-000291 Filed 2026-11-12 Dispute this row
MPM BIOIMPACT LLC 1,821,951 SH24,541,680 dollarsLower by 60,211 Prior quarter: 1,882,162Open filing 0001193125-26-463462 Filed 2026-11-16 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager1,801,571 SH24,267,162 dollarsLower by 650,225 Prior quarter: 2,451,796Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
Integral Health Asset Management, LLC 1,700,000 SH20,205,000 dollarsLower by 200,000 Prior quarter: 1,900,000Open filing 0001172661-26-005192 Filed 2026-11-16 Dispute this row
Qube Research Technologies Ltd 1,642,227 SH22,120,798 dollarsHigher by 847,685 Prior quarter: 794,542Open filing 0001729829-26-000018 Filed 2026-11-13 Dispute this row
ALGERT GLOBAL LLC Partly reported under another manager1,621,908 SH21,847,101 dollarsHigher by 406,615 Prior quarter: 1,215,293Open filing 0001275218-26-000018 Filed 2026-11-17 Dispute this row
First Turn Management, LLC 1,574,334 SH21,206,279 dollarsLower by 442,950 Prior quarter: 2,017,284Open filing 0001993440-26-000005 Filed 2026-11-16 Dispute this row
ORBIMED ADVISORS LLC 1,555,900 SH20,957,973 dollarsLower by 459,100 Prior quarter: 2,015,000Open filing 0001172661-26-005349 Filed 2026-11-16 Dispute this row
Paradigm Biocapital Advisors LP 1,505,769 SH20,282,708 dollarsNot in the prior quarter’s filings read Open filing 0001855655-26-000020 Filed 2026-11-16 Dispute this row
Woodline Partners LP 1,433,961 SH19,315,455 dollarsHigher by 186,446 Prior quarter: 1,247,515Open filing 0001172661-26-005063 Filed 2026-11-16 Dispute this row
ADAGE CAPITAL PARTNERS GP, L.L.C. 1,286,565 SH17,330,031 dollarsHigher by 234,662 Prior quarter: 1,051,903Open filing 0001172661-26-005200 Filed 2026-11-16 Dispute this row
Casdin Capital, LLC 1,250,000 SH16,837,500 dollarsNot in the prior quarter’s filings read Open filing 0000919574-26-008113 Filed 2026-11-16 Dispute this row
BANK OF AMERICA CORP /DE/ Partly reported under another manager1,039,224 SH13,998,348 dollarsLower by 38,831 Prior quarter: 1,078,055Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row
Squadron Capital Management LLC 1,000,000 SH13,470,000 dollarsNot in the prior quarter’s filings read Open filing 0002050709-26-000036 Filed 2026-11-16 Dispute this row
BRAIDWELL LP 990,959 SH13,348,218 dollarsLower by 223,581 Prior quarter: 1,214,540Open filing 0001420506-26-002894 Filed 2026-11-16 Dispute this row
Euclidean Capital LLC 989,410 SH13,327,353 dollarsUnchanged Prior quarter: 989,410Open filing 0001012975-26-001061 Filed 2026-11-16 Dispute this row
Vivo Capital, LLC 924,392 SH12,451,560 dollarsLower by 924,394 Prior quarter: 1,848,786Open filing 0001213900-26-119459 Filed 2026-11-13 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager803,245 SH10,819,710 dollarsLower by 3,059 Prior quarter: 806,304Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
Candriam S.C.A. 788,125 SH10,654,831 dollarsLower by 391,643 Prior quarter: 1,179,768Open filing 0001537014-26-000009 Filed 2026-11-03 Dispute this row
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 771,418 SH10,391,000 dollarsHigher by 93,595 Prior quarter: 677,823Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row
Frazier Life Sciences Management, L.P. 751,672 SH10,125,022 dollarsNot in the prior quarter’s filings read Open filing 0001892134-26-000007 Filed 2026-11-16 Dispute this row
MILLENNIUM MANAGEMENT LLC 713,325 SH9,608,488 dollarsHigher by 15,631 Prior quarter: 697,694Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row
SILVERARC CAPITAL MANAGEMENT, LLC Option: Call 702,400 SH9,461,328 dollarsHigher by 19,800 Prior quarter: 682,600Open filing 0001420506-26-002577 Filed 2026-11-12 Dispute this row
NEXTBio Capital Management LP 684,476 SH9,219,892 dollarsLower by 21,648 Prior quarter: 706,124Open filing 0001172661-26-004969 Filed 2026-11-13 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 648,205 SH8,731,321 dollarsHigher by 19,523 Prior quarter: 628,682Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
VANGUARD FIDUCIARY TRUST CO 604,415 SH8,141,470 dollarsHigher by 38,377 Prior quarter: 566,038Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
AQR CAPITAL MANAGEMENT LLC Partly reported under another manager588,639 SH7,928,968 dollarsHigher by 229,888 Prior quarter: 358,751Open filing 0001167557-26-000324 Filed 2026-11-16 Dispute this row
ArrowMark Colorado Holdings LLC 582,875 SH7,851,326 dollarsUnchanged Prior quarter: 582,875Open filing 0001172661-26-005265 Filed 2026-11-16 Dispute this row
Connor, Clark Lunn Investment Management Ltd. 556,369 SH7,494,290 dollarsHigher by 37,909 Prior quarter: 518,460Open filing 0001596800-26-000018 Filed 2026-11-10 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • EVENTIDE ASSET MANAGEMENT, LLC 954,768 SH
  • Jones Hill Capital LP 747,313 SH
  • Sixth Street Partners Management Company, L.P. 677,823 SH
  • SUPERSTRING CAPITAL MANAGEMENT LP 406,077 SH
  • Blue Owl Capital Holdings LP 400,000 SH
  • Boxer Capital Management, LLC 350,000 SH
  • SPHERA FUNDS MANAGEMENT LTD. 100,000 SH
  • SG Americas Securities, LLC 52,089 SH
  • Caption Management, LLC 48,130 SH
  • Sound Capital Solutions LLC 32,216 SH
  • Balyasny Asset Management L.P. 24,201 SH
  • INTECH INVESTMENT MANAGEMENT LLC 20,143 SH
  • Blueshift Asset Management, LLC 15,371 SH
  • Jupiter Topco LLC 14,400 SH
  • DRW Securities, LLC 14,312 SH
  • E Fund Management Co., Ltd. 12,798 SH
  • CANADA PENSION PLAN INVESTMENT BOARD 11,800 SH
  • PRELUDE CAPITAL MANAGEMENT, LLC 11,300 SH
  • Quantbot Technologies LP 4,280 SH
  • Integrated Wealth Concepts LLC 3,497 SH
  • Pacer Advisors, Inc. 1,516 SH
  • SIMPLEX TRADING, LLC 400 SH
  • Optiver Holding B.V. 248 SH
  • State of Wyoming 89 SH
  • Stone House Investment Management, LLC 18 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
EcoR1 Capital, LLC Common Stock2.93,028,11609/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0000935836-26-000590 Dispute this row
Oleg Nodelman Common Stock2.93,028,11609/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0000935836-26-000590 Dispute this row
EcoR1 Capital Fund Qualified, L.P. Common Stock2.82,885,43509/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0000935836-26-000590 Dispute this row
T. Rowe Price Associates, Inc. COMMON STOCK4.95,088,49509/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0000080255-26-000706 Dispute this row
VIKING GLOBAL INVESTORS LP Common Stock, $0.0001 par value per share5.76,002,98909/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0000905148-26-004951 Dispute this row
Viking Global Opportunities Parent GP LLC Common Stock, $0.0001 par value per share5.76,002,98909/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0000905148-26-004951 Dispute this row
Viking Global Opportunities GP LLC Common Stock, $0.0001 par value per share3.53,766,11109/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0000905148-26-004951 Dispute this row
Viking Global Opportunities Portfolio GP LLC Common Stock, $0.0001 par value per share3.53,766,11109/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0000905148-26-004951 Dispute this row
Viking Global Opportunities Illiquid Investments Sub-Master LP Common Stock, $0.0001 par value per share3.53,766,11109/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0000905148-26-004951 Dispute this row
Viking Global Opportunities Drawdown GP LLC Common Stock, $0.0001 par value per share2.12,236,87809/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0000905148-26-004951 Dispute this row
Viking Global Opportunities Drawdown Portfolio GP LLC Common Stock, $0.0001 par value per share2.12,236,87809/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0000905148-26-004951 Dispute this row
Viking Global Opportunities Drawdown (Aggregator) LP Common Stock, $0.0001 par value per share2.12,236,87809/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0000905148-26-004951 Dispute this row
HALVORSEN OLE ANDREAS Common Stock, $0.0001 par value per share5.76,002,98909/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0000905148-26-004951 Dispute this row
Shabet Rose Sharon Common Stock, $0.0001 par value per share5.76,002,98909/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0000905148-26-004951 Dispute this row
VIKING GLOBAL INVESTORS LP Common Stock, $0.0001 par value per share7.88,264,60703/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 3Open filing 0000905148-26-002430 Dispute this row
Viking Global Opportunities Parent GP LLC Common Stock, $0.0001 par value per share7.88,264,60703/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 3Open filing 0000905148-26-002430 Dispute this row
Viking Global Opportunities GP LLC Common Stock, $0.0001 par value per share55,250,10303/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 3Open filing 0000905148-26-002430 Dispute this row
Viking Global Opportunities Portfolio GP LLC Common Stock, $0.0001 par value per share55,250,10303/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 3Open filing 0000905148-26-002430 Dispute this row
Viking Global Opportunities Illiquid Investments Sub-Master LP Common Stock, $0.0001 par value per share55,250,10303/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 3Open filing 0000905148-26-002430 Dispute this row
Viking Global Opportunities Drawdown GP LLC Common Stock, $0.0001 par value per share2.83,014,50403/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 3Open filing 0000905148-26-002430 Dispute this row
Viking Global Opportunities Drawdown Portfolio GP LLC Common Stock, $0.0001 par value per share2.83,014,50403/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 3Open filing 0000905148-26-002430 Dispute this row
Viking Global Opportunities Drawdown (Aggregator) LP Common Stock, $0.0001 par value per share2.83,014,50403/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 3Open filing 0000905148-26-002430 Dispute this row
HALVORSEN OLE ANDREAS Common Stock, $0.0001 par value per share7.88,264,60703/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 3Open filing 0000905148-26-002430 Dispute this row
Shabet Rose Sharon Common Stock, $0.0001 par value per share7.88,264,60703/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 3Open filing 0000905148-26-002430 Dispute this row
T. Rowe Price Associates, Inc. COMMON STOCK5.45,387,78303/31/2026 Filed 2026-05-15SCHEDULE 13GOpen filing 0000080255-26-000420 Dispute this row
Venrock Healthcare Capital Partners III, L.P. Common Stock, par value $0.0001 per share4.24,319,765.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0001738048-26-000058 Dispute this row
VHCP Co-Investment Holdings III, LLC Common Stock, par value $0.0001 per share4.24,319,765.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0001738048-26-000058 Dispute this row
Venrock Healthcare Capital Partners EG, L.P. Common Stock, par value $0.0001 per share4.24,319,765.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0001738048-26-000058 Dispute this row
VHCP Management III, LLC Common Stock, par value $0.0001 per share4.24,319,765.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0001738048-26-000058 Dispute this row
VHCP Management EG, LLC Common Stock, par value $0.0001 per share4.24,319,765.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0001738048-26-000058 Dispute this row
Nimish Shah Common Stock, par value $0.0001 per share4.24,319,765.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0001738048-26-000058 Dispute this row
Bong Y. Koh Common Stock, par value $0.0001 per share4.24,319,765.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0001738048-26-000058 Dispute this row
Point72 Asset Management, L.P. Common Stock, par value $0.0001 per share00.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-003469 Dispute this row
Point72 Capital Advisors, Inc. Common Stock, par value $0.0001 per share00.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-003469 Dispute this row
Steven A. Cohen Common Stock, par value $0.0001 per share00.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-003469 Dispute this row
Venrock Healthcare Capital Partners III, L.P. Common Stock, par value $0.0001 per share5.85,676,230.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001738048-26-000026 Dispute this row
VHCP Co-Investment Holdings III, LLC Common Stock, par value $0.0001 per share5.85,676,230.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001738048-26-000026 Dispute this row
Venrock Healthcare Capital Partners EG, L.P. Common Stock, par value $0.0001 per share5.85,676,230.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001738048-26-000026 Dispute this row
VHCP Management III, LLC Common Stock, par value $0.0001 per share5.85,676,230.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001738048-26-000026 Dispute this row
VHCP Management EG, LLC Common Stock, par value $0.0001 per share5.85,676,230.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001738048-26-000026 Dispute this row
Nimish Shah Common Stock, par value $0.0001 per share5.85,676,230.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001738048-26-000026 Dispute this row
Bong Y. Koh Common Stock, par value $0.0001 per share5.85,676,230.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001738048-26-000026 Dispute this row
BlackRock, Inc. Common Stock5.65,473,14512/31/2025 Filed 2026-01-21SCHEDULE 13GOpen filing 0002012383-26-000702 Dispute this row
The Column Group II, LP Common Stock, $0.0001 par value per share3.63,540,77709/30/2025 Filed 2025-11-17SCHEDULE 13G/AAmendment 3Open filing 0001193125-25-284976 Dispute this row
The Column Group II GP, LP Common Stock, $0.0001 par value per share3.63,540,77709/30/2025 Filed 2025-11-17SCHEDULE 13G/AAmendment 3Open filing 0001193125-25-284976 Dispute this row
David V Goeddel Common Stock, $0.0001 par value per share3.73,627,49309/30/2025 Filed 2025-11-17SCHEDULE 13G/AAmendment 3Open filing 0001193125-25-284976 Dispute this row
Peter Svennilson Common Stock, $0.0001 par value per share3.73,644,11809/30/2025 Filed 2025-11-17SCHEDULE 13G/AAmendment 3Open filing 0001193125-25-284976 Dispute this row
Alkeon Capital Management LLC Common Stock, par value $0.0001 per share4.64,504,096.0009/30/2025 Filed 2025-11-13SCHEDULE 13G/AAmendment 3Open filing 0000902664-25-004920 Dispute this row
Panayotis D. Sparaggis Common Stock, par value $0.0001 per share4.64,504,096.0009/30/2025 Filed 2025-11-13SCHEDULE 13G/AAmendment 3Open filing 0000902664-25-004920 Dispute this row
SR One Capital Management, LLC Common Stock, $0.0001 par value per share4.754,615,38408/12/2025 Filed 2025-08-14SCHEDULE 13D/AAmendment 1Open filing 0000950170-25-108850 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,722,084 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015138,466
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,828

Filings made before the SEC required XML are listed, not extracted.

Back to ORIC Pharmaceuticals, Inc.